At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 17 enrolled
Drug / intervention
CRS3123 200 mg capsuledrug
Likely dose
CRS3123 200 mg capsulefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Single-Center, Open-Label, Randomized, Single-Dose, 2-Period, Crossover Study to Evaluate the Potential Impact of High-fat Meal on the Pharmacokinetics of CRS3123 200 mg Capsule in Healthy Adult Participants
In Brief
A Phase 1 clinical trial evaluating CRS3123 200 mg capsule for Food Effect in Healthy Participants. Completed, enrolled 17 participants across 1 site.
Detailed Summary
This study will explore the potential effects of high-fat meal on the plasma pharmacokinetics (PK) of CRS3123 when administered as a single oral dose of 200 mg in healthy adult participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFood Effect in Healthy Participants
CountriesUnited States
Timeline
Phase 1CompletedFinished
2026
Enrollment StartApr 2025
First PostedMay 2025
Primary CompletionJun 2025
TodayJul 2026
First PostedMay 23, 2025
Enrollment StartApr 21, 2025
Primary CompletionJun 4, 2025
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 1.1 years ago
Interventions
CRS3123 200 mg capsuledrug
CRS3123 200 mg capsule given as a single oral dose